论文部分内容阅读
单、复方阿米洛利治疗心力衰竭109例,采用双盲、随机、分层自身及组间对照,疗程两周,分四个组:Ⅰ组阿米洛利5mg加氢氯噻嗪(双氢克尿塞)50mg/日;Ⅱ组阿米洛利5mg加氢氯噻嗪25mg/日;Ⅲ组阿米洛利10mg分2次服;Ⅳ组氨苯蝶啶50mg,每日3次。结果:四个组均有保钾利尿作用,但Ⅰ组利尿作用优于Ⅱ和Ⅲ组.Ⅲ组优于Ⅳ组(P<0.01及P<0.05)。Ⅲ组保钾作用较好,自身前后血钾P<0.05。四个组尿钾排出均较治疗前减少,自身对照P均<0.01。Ⅰ、Ⅱ、Ⅲ组中共7例治疗后室早消失。其中4例原有低钾心电图表现者亦恢复,故认为此药对心力衰竭保钾利尿作用良好。
Single and compound amiloride treatment of heart failure in 109 cases, using double-blind, randomized, stratified their own and between the control group, treatment for two weeks, divided into four groups: Ⅰ amiloride 5mg hydrochlorothiazide (hydrochlorothiazide) 50mg / Day; amiloride group 5mg hydrochlorothiazide 25mg / day; Ⅲ amiloride 10mg sub-2 service; Ⅳ group triamterene 50mg, 3 times a day. Results: All four groups had potassium-sparing and diuretic effects, but diuretic effect of group Ⅰ was superior to group Ⅱ and Ⅲ, and group Ⅲ was superior to group Ⅳ (P <0.01 and P <0.05). Group Ⅲ potassium is better, before and after its own potassium P <0.05. Four groups of urinary potassium excretion decreased compared with before treatment, their own control P <0.01. Seven patients in group Ⅰ, Ⅱ and Ⅲ disappeared early after treatment. Among them, 4 cases of original hypokalemia electrocardiogram also recovered, so that this medicine has a good effect on potassium deficiency and diuretic of heart failure.